Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus

Area of Science:

• Oncolytic virotherapy
• Cancer biology
• Gene therapy

Background:

• Osteosarcoma is a challenging bone cancer with limited treatment options.
• Telomerase is a key enzyme overexpressed in many cancer cells, including osteosarcoma.
• Oncolytic viruses offer a targeted approach to cancer treatment by selectively replicating in and destroying tumor cells.

Purpose of the Study:

• To evaluate the oncolytic efficacy of Telomelysin, a telomerase-specific oncolytic adenovirus, against human osteosarcoma.
• To assess the safety and tumor-targeting capabilities of Telomelysin in vitro and in vivo.

Main Methods:

• In vitro studies on human osteosarcoma cell lines and normal cell lines.
• In vivo studies using a mouse xenograft model of human osteosarcoma.
• Assessed viral replication, cytotoxicity, apoptosis induction, and tumor growth suppression.

Main Results:

• Telomelysin demonstrated efficient replication and selective killing of osteosarcoma cells, with dose- and time-dependent effects.
• Significant tumor growth suppression and induction of apoptosis were observed in vivo.
• No significant cytotoxicity or apoptosis was detected in normal human cell lines, indicating a favorable safety profile.

Conclusions:

• Telomelysin exhibits potent oncolytic activity against human osteosarcoma.
• Virotherapy with Telomelysin represents a promising therapeutic strategy for osteosarcoma treatment.